All In Biotech

NDA 208271 · Salix

Relistor

Methylnaltrexone Bromide · Oral

Last checked: Nov 19, 2026Latest source record: Mar 14, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jul 19, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

17 Phase 3, 2 recruiting

FAERS reports

1,520

905 serious, 335 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 1, 2024.

• RELISTOR is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.1 ) • RELISTOR injection is indicated for the treatment of OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care. ( 1.2 ) 1.1 Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. 1.2 Opioid-Induced Constipation in Adult Patients with Advanced Illness RELISTOR injection is indicated for the treatment of OIC in adult patients with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care.

Mechanism: Methylnaltrexone is a selective antagonist of opioid binding at the mu-opioid receptor. As a quaternary amine, the ability of methylnaltrexone to cross the blood-brain barrier is restricted. This allows methylnaltrexone to function as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids without impacting opioid-mediated analgesic effects on the central nervous system (CNS).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • RELISTOR · METHYLNALTREXONE BROMIDE 150MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylnaltrexone" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death246
  • drug ineffective208
  • nausea118
  • constipation113
  • abdominal pain106
  • pain84
  • diarrhoea81
  • vomiting77
  • fatigue67
  • headache58
  • abdominal pain upper57
  • off label use51

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
200810
200938
201044
201161
201225
201325
201440
201549
2016144
2017166
2018137
2019217
2020148
2021109
202271
202362
202459
202561
202653

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Relistor* (Methylnaltrexone Bromide)

2024 spending

$135M

Beneficiaries

15,616

56,864 claims

Per beneficiary

$8,617

$52.67 per unit

View as table
YearSpending
2020$82,678,459
2021$95,717,741
2022$117,077,748
2023$132,882,335
2024$134,570,150

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 79 on PubMed

Sponsor: Salix

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.